Business
TerrAscend to Present at 2019 GMP Securities Cannabis Conference
TerrAscend to Present at 2019 GMP Securities Cannabis Conference Canada NewsWire ...
About this update from Terrascend Corp.
[{"type":"text","content":"\n\n\n\nTerrAscend to Present at 2019 GMP Securities Cannabis Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, April 12, 2019\n\n\n\nSenior leaders to provide insight into TerrAscend's recent success and growth potential \n TORONTO, April 12, 2019 /CNW/ - Senior executives from TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (\"TerrAscend\"), a leading North American Operator with a strong presence across the entire cannabis value chain, will attend GMP Securities' 2019 Cannabis Conference to be held April 16, 2019 at the Ritz-Carlton Hotel in Toronto.\n\n \n \n\n \nTerrAscend President Matthew Johnson will share highlights of TerrAscend's strategy and operations, including plans for expansion through organic growth, acquisitions, and partnerships in North America and globally. He will present at 3PM EDT in the Ritz-Carlton Ballroom. \nFor more information, please reach out to the TerrAscend investor relations team: [email protected].\nAbout TerrAscendTerrAscend is a biopharmaceutical and wellness company that is committed to quality products, brands, and services for the global cannabinoid market. The Company participates in the medical and legal adult-use market in Canada and in US states where cannabis has been legalized for therapeutic or adult-use. TerrAscend operates a number of synergistic businesses, including Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products, Ascendant Laboratories Inc., a biotechnology and licensing Company committed to the continuous improvement of cannabinoid expressing plants, and Solace RX Inc., a proposed drug preparation premises focused on the development of novel formulations and dosage forms.\nCaution Regarding Cannabis Operations in the United StatesInvestors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States.  Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United St...